Radioactive Iodine for the Treatment of Subclinical Thyrotoxicosis Grade 1 and 2: Outcome of up to 18-Year Follow Up.
Front Endocrinol (Lausanne). 2022 Mar 9;13:843857. doi: 10.3389/fendo.2022.843857. eCollection 2022.
Front Endocrinol (Lausanne). 2022.
PMID: 35370990
Free PMC article.